Navigation Links
Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Date:9/5/2007

h respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

For Gen
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
2. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
3. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
4. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
5. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
8. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , HARBIN, China, Nov. 17 /PRNewswire-Asia-FirstCall/ ... Company") (Nasdaq: CSKI ), a,leading fully integrated pharmaceutical company in ... the third quarter,of 2009. , , Third Quarter ... to $43.2 million, -- Gross profit increased 44.8% ...
... Mass., Nov. 17 Decision Resources, one of the world,s ... finds that, driven by the continued dominance of opioids that ... cancer pain drug market will increase from $2.3 billion in ... France, Germany, Italy, Spain, the United Kingdom and Japan. , ...
Cached Medicine Technology:China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 2China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 3China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 4China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 5China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 6China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 7China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 8China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 9China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 10The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... more than one out of three survivors of ... in The Lancet Respiratory Medicine , and ... rather than mentally. , It is one of ... and functional outcomes of critical care survivors, according ... of Medicine, and it highlights a significant public ...
(Date:4/24/2014)... team of researchers was the first in the world ... a tumour of the jaw. , Ameloblastoma is an ... treatment. Ameloblastoma is most often found in the posterior ... often resulting in tissue deficiencies in the jaws as ... therapy could reduce the need for surgery and the ...
(Date:4/24/2014)... University researcher has found a relationship between motor skill ... spectrum disorder in very young children. , The ... a direct relationship between motor skills and autism severity, ... should be included in treatment plans for young children ... OSU,s College of Public Health and Human Sciences. ...
(Date:4/24/2014)... 2009 the influenza pH1N1 virus caused the first flu ... in May 2009 and killed more than 50 people ... Finns mainly during flu epidemics (winter/spring seasons). , ... serious complicated illnesses. World Health Organization has recommended Tamiflu ... The disadvantage of this drug is that it targets ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
... Goodman Steps Down; John Walker, Board Chair, Named Executive ... ... Renovis,Inc. (Nasdaq: RNVS ), a biopharmaceutical company focused on the ... and inflammatory diseases, today announced that Corey Goodman,Ph.D., will step down today ...
... approve gastric band for adolescents by 2009, WALTHAM, ... gastric band market, currently valued at over $190,million, will ... approval,of the LAP-BAND device for adolescents aged 14 to ... of the most rapidly growing,segments of the obese population, ...
... Concentra was recently announced,as a silver ... Awards, sponsored by,ComPsych Corporation. Concentra was selected ... participation rates,and achieved results. Concentra, a ... for its commitment to better health and ...
... Oct. 1 Mylan Laboratories Inc.,(NYSE: MYL ) ... Vice,President and Treasurer, effective October 22, 2007. Mr. Byala ... with responsibility for,treasury planning in both New York and ... in various treasury positions of increasing responsibility.,Prior to Pfizer, ...
... Inc., a leader,in healthcare payment and cost management ... Inc. for $54 million, consisting of $44,million in ... common,stock. The acquisition will expand Viant,s PPO network ... existing lines of services to the,nation,s leading health ...
... LeMaitre Vascular,Inc., (Nasdaq: LMAT ), a provider ... has reached an agreement to launch a,direct sales force ... sells its products in Italy through an,exclusive distribution agreement ... to terminate Serom,s exclusive rights on,January 25, 2008 in ...
Cached Medicine News:Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:The Skinny on Teen Surgery 2Health News:Concentra Honored With Silver Health at Work(SM) Award by ComPsych(R) Corp. 2Health News:Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer 2Health News:Viant Acquires Texas True Choice 2Health News:LeMaitre Vascular to Start Italian Sales Force 2Health News:LeMaitre Vascular to Start Italian Sales Force 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: